# Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

> **NCT02727881** · PHASE3 · UNKNOWN · sponsor: **Ohr Pharmaceutical Inc.** · enrollment: 230 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** Squalamine lactate ophthalmic solution, 0.2%
- **DRUG:** Placebo Ophthalmic solution
- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT02727881
- **Lead sponsor:** Ohr Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04-12
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2017-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02727881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02727881, "Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02727881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*